Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits.
O'Byrne
E M
EM
Research Department, Ciba-Geigy Corporation, Summit, NJ 07901, USA.
Parker
D T
DT
Roberts
E D
ED
Goldberg
R L
RL
MacPherson
L J
LJ
Blancuzzi
V
V
Wilson
D
D
Singh
H N
HN
Ludewig
R
R
Ganu
V S
VS
D000818:Animals; D002358:Cartilage, Articular / Q000378:metabolism / Q000473:pathology*; D006614:Hindlimb / Q000473:pathology; D006877:Hydroxamic Acids; D007596:Joints / Q000473:pathology; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D010003:Osteoarthritis / Q000473:pathology / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011509:Proteoglycans / Q000378:metabolism*; D011719:Pyrazines; D011817:Rabbits; D013449:Sulfonamides
C097658:CGS 27023A; D006877:Hydroxamic Acids; D011480:Protease Inhibitors; D011509:Proteoglycans; D011719:Pyrazines; D013449:Sulfonamides; D008666:Metalloendopeptidases